arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Equillium, Inc.

EQ
$1.75 ▼ -0.17 (-9.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
10 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Equillium, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $100.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -82.6% ↘
FCF / Share $-0.40 ↗
Trailing P/E —
Price / Book 3.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.09M
↑ +13.9% —
Net Income Profit after all expenses
$-22.40M
↓ -177.6% —
Operating Margin Operating profit as % of sales
-20.1%
↑ +50.0% —
FCF / Share Free cash flow per share
$-0.40
↑ +26.4% —
Long-Term Debt Long-term obligations
$9.07M
↓ -6.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
11
Cash Quality ↑
66

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 37 quarters